# Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects

Study · id `cardio:ct-nct03485092` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03485092](<https://clinicaltrials.gov/study/NCT03485092>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03485092

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 105 participants.

## Technical summary

Registry record NCT03485092. Randomized; quadruple masking; primary purpose treatment. Start 2018-03-16 (actual); primary completion 2020-03-28 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 105 participants (enrolled count; ClinicalTrials.gov record NCT03485092, source copy `cardio:ctgov-nct03485092-2020-09-18`, retrieved 2026-10-26)
- Started: 2018-03-16 (actual) (ClinicalTrials.gov record NCT03485092, source copy `cardio:ctgov-nct03485092-2020-09-18`, retrieved 2026-10-26)
- Primary completion: 2020-03-28 (actual) (ClinicalTrials.gov record NCT03485092, source copy `cardio:ctgov-nct03485092-2020-09-18`, retrieved 2026-10-26)
- Completion: 2020-03-28 (actual) (ClinicalTrials.gov record NCT03485092, source copy `cardio:ctgov-nct03485092-2020-09-18`, retrieved 2026-10-26)
- Countries: United Kingdom (ClinicalTrials.gov record NCT03485092, source copy `cardio:ctgov-nct03485092-2020-09-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03485092-2020-09-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects
- Acronym: SUGAR-DM-HF
- Condition: Heart Failure
- Condition: Diabetes Mellitus
- Intervention (Drug): Empagliflozin 10 MG
- Intervention (Drug): Placebo Oral Tablet
- Lead sponsor: NHS Greater Glasgow and Clyde
- Lead sponsor class: OTHER
- Collaborator: University of Glasgow
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Empagliflozin (`cardio:empagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: NHS Greater Glasgow and Clyde (`cardio:org-nhs-greater-glasgow-and-clyde`)
- Registry lists this organization as a collaborator: University of Glasgow (`cardio:org-university-of-glasgow`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF) (`cardio:pubmed-33186500`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 12549386753f18d01608dbccf4eea278072e4520bf8a60bbcd5c7c7798bd19e5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
